FOURKITES
6.4.2022 10:38:09 CEST | Business Wire | Press release
FourKites ® , the #1 real-time supply chain visibility platform, today launches Slot Manager, its universal time slot booking solution, across Europe. The cloud-based solution helps warehouses, distribution centers and manufacturing facilities collaborate efficiently on pickup and receiving time slots, saving significant time and improving daily operations and partner relationships. In addition, the highly configurable solution allows shippers and carriers to eliminate excess dwell time on site, eliminating detention fees and significantly reducing carbon emissions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220406005544/en/
Time slot management is a notoriously time-consuming task for shippers and carriers alike. With carrier dwell averaging up to 4.35 hours per day, or nearly half of a driver’s time, Slot Manager improves facility productivity and reduces carrier wait time by more than 50%. Highly configurable for personalised requirements, Slot Manager enables shippers and carriers to collaborate in real time, and allows carriers to self-book their preferred time slot based on real-time transit conditions, thereby eliminating hours of daily administrative work and error-prone manual processes.
Slot Manager is an extension of FourKites’ Appointment ManagerSM , launched over two years ago. The solution is now also available in several new Asia-Pacific markets, including Australia, New Zealand and India.
Specifically, Slot Manager offers the following benefits:
- Labor optimisation : Leveraging FourKites’ Dynamic ETA® to provide the most accurate times of arrival, teams can better allocate labor and resources based on real-time data and shifts in expected arrival time.
- Ease and compliance with carrier scheduling : Slot Manager creates a single appointment layer accessible to both shippers and carriers to streamline communication and facilitate collaboration. Slots are created by the facility to ensure adherence to preferred scheduling, business rules and specific commodity requirements.
- True end-to-end visibility : Powered by real-time supply chain visibility data from FourKites, Slot Manager extends visibility even further into the facility via one streamlined interface. With FourKites, stakeholders receive a comprehensive end-to-end view of shipments from point of origin to predictive insights that help orchestrate activities in the facility.
- Diminished carrier detention costs : With optimised scheduling, carrier dwell on site can be virtually eliminated, helping shippers avoid detention fees and fines for truck queues on public roads.
- Reduced carbon emissions : Scheduling and operational efficiencies driven by Slot Manager reduce time carriers spend in the yard by up to 50%, cutting carbon dioxide emissions by an average of 54%.
“We are excited to introduce the easiest, most flexible slot booking application on the market,” said Mathew Elenjickal, FourKites Founder and CEO. “This groundbreaking solution helps shippers across the globe optimise end-to-end visibility, efficiency and sustainability, as well as adapt quickly as their business needs change. We’re thrilled to be launching Slot Manager in Europe, specifically tailored to the needs of local facilities.”
In addition, FourKites has partnered with French transportation solutions firm IER , a Blue Systems entity (Bolloré Group), to facilitate integrated implementation in Europe, driving greater efficiency for both carriers and facilities. The partnership combines IER’s leading standard of facility hardware technology with facility processes for automated check-in and check-out. When combined with FourKites’ advanced data capture and processing capabilities, the companies’ combined pre-configured integration offers a fast, turnkey facility solution for customers.
"We chose to partner with FourKites due to their globally recognised data quality and their commitment to delivering that data back to customers with actionable insights," said Christophe Levy, Chief Executive Officer of IER’s Track & Trace Unit. "By combining FourKites’ advanced supply chain intelligence capabilities with our leading facility hardware capabilities, we offer a seamlessly integrated solution that helps customers achieve immediate results for their business."
About FourKites
FourKites® is the #1 supply chain visibility platform in the world, extending visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 185 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005544/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom